Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ROCHE FARMA, SA
- Phase: III
- Execution start: 21/06/2021
- End of execution: 21/06/2023
- IP: ANA DOLORES ROMERO ORTIZ